Furthermore, the presence of RAS/TP53 pathway alterations, particularly prevalent in ALT-positive relapsed neuroblastomas but consistently elevated across all ALT-positive neuroblastomas [3], has emerged as a critical determinant in characterizing UHR neuroblastoma among TMM-positive patients [8,10,17]. This evidence concerns the gene TP53 and neuroblastoma.